{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:20:52Z","timestamp":1694632852487},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1007\/bf02938365","type":"journal-article","created":{"date-parts":[[2008,8,15]],"date-time":"2008-08-15T06:57:45Z","timestamp":1218783465000},"page":"381-386","source":"Crossref","is-referenced-by-count":2,"title":["Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators"],"prefix":"10.1007","volume":"9","author":[{"given":"James A.","family":"Reiffel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02938365_CR1","first-page":"545","volume":"10","author":"JA Reiffel","year":"2005","unstructured":"Reiffel JA:Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.J Cardiovasc Therapeut 2005,10:545\u2013558.","journal-title":"J Cardiovasc Therapeut"},{"key":"BF02938365_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.hco.0000198978.55637.b5","volume":"21","author":"G Duray","year":"2006","unstructured":"Duray G, Israel CW, Hohnloser SH:Recent primary prevention implantable cardioverter defibrillator trials.Curr Opin Cardiol 2006,21:15\u201319.","journal-title":"Curr Opin Cardiol"},{"key":"BF02938365_CR3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1067\/mhj.2001.117129","volume":"142","author":"JS Steinberg","year":"2001","unstructured":"Steinberg JS, Martins J, Sadanandan S, et al.:Antiarrhythmic drug use in the implantable defibrillator arm of the AVID study.Am Heart J 2001,142:520\u2013529.","journal-title":"Am Heart J"},{"key":"BF02938365_CR4","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMra035432","volume":"49","author":"JP DiMarco","year":"2003","unstructured":"DiMarco JP:Implantable cardioverter-debrillators.N Engl J Med 2003,49:1836\u20131847.","journal-title":"N Engl J Med"},{"key":"BF02938365_CR5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9149(98)00468-8","volume":"82","author":"MJ Reiter","year":"1998","unstructured":"Reiter MJ, Reiffel JA:Importance of beta blockade in the therapy of serious ventricular arrhythmias.Am J Cardiol 1998,82:91\u2013191.","journal-title":"Am J Cardiol"},{"key":"BF02938365_CR6","first-page":"545","volume":"10","author":"JA Reiffel","year":"2005","unstructured":"Reiffel JA:Drug and drug-device therapy in heart failure patient in the post-COMET and SCD-HeFT era.J Cardiovasc Therapeut 2005,10:545\u2013558.","journal-title":"J Cardiovasc Therapeut"},{"issue":"Suppl 1","key":"BF02938365_CR7","first-page":"I-28","volume":"28","author":"JA Reiffel","year":"2005","unstructured":"Reiffel JA:Practical algorithms for pharmacologic management of the post myocardial infarction patient.Clin Cardiol 2005,28(Suppl 1):I-28\u2013I-37.","journal-title":"Clin Cardiol"},{"key":"BF02938365_CR8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0735-1097(99)00234-X","volume":"34","author":"DV Exner","year":"1999","unstructured":"Exner DV, Reiffel JA, Epstein AE, et al.:Beta blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia.J Am Coll Cardiol 1999,34:325\u2013333.","journal-title":"J Am Coll Cardiol"},{"key":"BF02938365_CR9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.amjcard.2005.04.046","volume":"96","author":"WN Brodine","year":"2005","unstructured":"Brodine WN, Tung RT, Lee JK, et al.:Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy [from the Multicenter Automatic Defibrillator Implantation Trial\u2014II].Am J Cardiol 2005,96:691\u2013695.","journal-title":"Am J Cardiol"},{"key":"BF02938365_CR10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0002-9149(98)00421-4","volume":"82","author":"JA Reiffel","year":"1998","unstructured":"Reiffel JA, Reiter MJ, Blitzer M:Antiarrhythmic drugs and devices for the management of ventricular tachyarrhythmias in ischemic heart disease.Am J Cardiol 1998,82:311\u2013401.","journal-title":"Am J Cardiol"},{"key":"BF02938365_CR11","volume-title":"Section on pharmacokinetics, antiarrhythmic drugs, proarrhythmia. Electrophysiology Self Assessment Program [EPSAP II]","author":"P Kowey","year":"2000","unstructured":"Kowey P, Reiffel JA:Section on pharmacokinetics, antiarrhythmic drugs, proarrhythmia. Electrophysiology Self Assessment Program [EPSAP II]. Bethesda, MD: American College of Cardiology; 2000."},{"key":"BF02938365_CR12","first-page":"15","volume-title":"Antiarrhythmic drugs. American College of Cardiology Self Assessment Program [ACCSAP], version 6, book 4","author":"JA Reiffel","year":"2005","unstructured":"Reiffel JA, Curtis AB:Antiarrhythmic drugs. American College of Cardiology Self Assessment Program [ACCSAP], version 6, book 4. Bethesda, MD: American College of Cardiology; 2005:15\u201353."},{"key":"BF02938365_CR13","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0002-9149(97)00045-3","volume":"79","author":"JA Reiffel","year":"1997","unstructured":"Reiffel JA, Hahn E, Hartz V, et al.:Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure.Am J Cardiol 1997,79:1048\u20131053.","journal-title":"Am J Cardiol"},{"key":"BF02938365_CR14","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199906173402402","volume":"340","author":"A Pacifico","year":"1999","unstructured":"Pacifico A, Hohnloser SH, Williams JH, et al.:Prevention of implantable defibrillator shocks by treatment with sotalol.N Engl J Med 1999,340:1855\u20131862.","journal-title":"N Engl J Med"},{"key":"BF02938365_CR15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0002-9149(98)00478-0","volume":"82","author":"K Seidl","year":"1998","unstructured":"Seidl K, Hauer B, Schwick NG, et al.:Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter\/defibrillator.Am J Cardiol 1998,82:744\u2013748.","journal-title":"Am J Cardiol"},{"key":"BF02938365_CR16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/clc.4960290303","volume":"29","author":"JA Reiffel","year":"2006","unstructured":"Reiffel JA, Naccarelli GV:Antiarrhythmic drug therapy for atrial fibrillation: are the guidelines guiding clinical practice? Clin Cardiol 2006,29:97\u2013102.","journal-title":"Clin Cardiol"},{"key":"BF02938365_CR17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","volume":"295","author":"SJ Connolly","year":"2006","unstructured":"Of major importance Connolly SJ, Dorian P, Roberts R, et al.:Comparison of beta blockers, amiodarone plus beta blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study: a randomized trial.JAMA 2006,295:165\u2013171. A significant prospective trial comparing the risks, benefits, and tolerance of multiple AAD in conjunction with ICD therapy.","journal-title":"JAMA"},{"key":"BF02938365_CR18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1161\/CIRCULATIONAHA.106.618421","volume":"114","author":"SH Hohnloser","year":"2006","unstructured":"Hohnloser SH, Dorian P, Roberts R, et al.:Effect of amiodarone and sotalol on ventricular defibrillation threshold: the Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) trial.Circulation 2006,114:104\u2013109.","journal-title":"Circulation"},{"key":"BF02938365_CR19","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1161\/01.CIR.99.17.2268","volume":"99","author":"F Boutitie","year":"1999","unstructured":"Boutitie F, Boissel JP, Connolly SJ, et al.:Amiodarone interactions with beta blockers: analysis of the merged EMIAT and CAMIAT databases.Circulation 1999,99:2268\u20132275.","journal-title":"Circulation"},{"key":"BF02938365_CR20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jacc.2003.07.033","volume":"43","author":"I Singer","year":"2004","unstructured":"Singer I, Al-Khalididi H, Niazi I, et al.:Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators.J Am Coll Cardiol 2004,43:39\u201343.","journal-title":"J Am Coll Cardiol"},{"key":"BF02938365_CR21","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1161\/01.CIR.0000149240.98971.A8","volume":"110","author":"P Dorian","year":"2004","unstructured":"Of major importance Dorian P, Borggrefe M, Al-Khalidi HR, et al.:Placebocontrolled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.Circulation 2004,110:3646\u20133654. An extremely well-done trial assessing the effect of azimilide in ICD patients; this trial is privotal in the Food and Drug Administration application for approval of azimilide for this indication.","journal-title":"Circulation"},{"key":"BF02938365_CR22","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0735-1097(98)00495-1","volume":"32","author":"SC Credner","year":"1998","unstructured":"Credner SC, Klingenheben T, Mauss O, et al.:Electrical storm in patients with transvenous implantable cardioverterdefibrillators: incidence, management, and prognostic implications.J Am Coll Cardiol 1998,32:1909\u20131915.","journal-title":"J Am Coll Cardiol"},{"key":"BF02938365_CR23","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1093\/eurheartj\/ehl276","volume":"37","author":"SH Hohnloser","year":"2006","unstructured":"Hohnloser SH, Al-Khalidi HR, Pratt CM, et al.:Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial.Eur Heart J 2006,37:3027\u20133032.","journal-title":"Eur Heart J"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02938365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02938365\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02938365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T01:25:34Z","timestamp":1631669134000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02938365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["BF02938365"],"URL":"https:\/\/doi.org\/10.1007\/bf02938365","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}